key: cord-0026453-pqhdvjuy
authors: Baughman, Robert P; Grutters, Jan C; Wells, Athol U; Azuma, Arata; Costabel, Ulrich; Drent, Marjolein; Lower, Elyse E; Culver, Daniel A
title: World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence
date: 2022-01-13
journal: Sarcoidosis Vasc Diffuse Lung Dis
DOI: 10.36141/svdld.v38i4.12620
sha: 93dee0907a025fe76a3f013be3251833a17b82bf
doc_id: 26453
cord_uid: pqhdvjuy

nan

The proposal for WASOG CoEs was first made by Drs. Baughman and Grutters in 2016. At the time, few guidelines existed for sarcoidosis centers of excellence. The Dutch had established national criteria and with the help of Dr Marlies Wijsenbeek, Drs Grutters and Baughman sent a questionnaire to sarcoidosis centers across the world. Simultaneously, a selection committee for the WASOG Centers of Excellence (WASOG CoE) was established ( Table 2) . This committee included health care providers and sarcoidosis patients from the Foundation for Sarcoidosis Research and European Lung Foundation. In addition, Kelly Bauer and later Lesley Baxter from the Foundation for Sarcoidosis Research assisted in the collection of questionnaires.

The selection committee for the WASOG CoE reviewed the results from the questionnaires and developed a second questionnaire that was sent to all applicants. In addition, the WASOG CoE selection committee graded individual items (Table 3) based on the committee's ranking of level of importance. Most important features for a center of excellence included patient access to center, an established registry of patients, sufficient numbers of sarcoidosis patients, access to sarcoidosis experienced multispecialty disciplines, and published original research in sarcoidosis.

The WASOG CoE designation was never intended to be static. Drs. Culver and Wells have assumed co-chairship of the committee and current and potential centers are asked to apply for renewal or new CoE membership, respectively. Because of the COVID-19 pandemic, this round of applications has been placed on hold until 2022. At that time, all current and potential new centers will be evaluated in a blinded fashion. New and updated features have been added to the next evaluation process. Each WASOG CoE will need to identify at least one sarcoidosis generalist, who has a comprehensive view of the various phenotypes and complications of the disease. In addition to assure standard criteria global compliance, all potential WASOG CoE sites will undergo a virtual or in-person site visit. Patient experience criteria will also be incorporated in future versions of the CoE application.

Over the past few years, WASOG and the academic community have made great strides in providing evidence-based guidelines for the diagnosis (1) and treatment (2) of sarcoidosis as well as guidance on the diagnosis and management of sarcoidosis associated pulmonary hypertension (in press). In the future, the application of these guidelines may prove useful in assessing WASOG CoE. 

Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline

ERS clinical practice guidelines on treatment of sarcoidosis